13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001395064
Total reported value
$16.4M
$16.4M
11 檔
88.5%
In Q1 2025, Takeda Pharmaceutical Co LTD's U.S. equity holdings reached a combined market value of $16.4M, distributed across 11 disclosed stock positions.
During Q1 2025, Takeda Pharmaceutical Co LTD's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ✓ | Hillevax Inc | Stock-Other | 60.21% | -60.21% | EXIT | |
| 2 | OVID | Ovid Therapeutics Inc | Stock-Other | 14.51% | +45.31% | — | |
| 3 | ✓ | Xilio Therapeutics Inc | Stock-Other | 6.59% | +0.99% | — | |
| 4 | EQ | Equillium Inc | Stock-Other | 4.40% | +11.54% | — | |
| 5 | AMWL | American Well Corp-class A | Stock-Other | 3.78% | -0.86% | — | |
| 6 | STTK | Shattuck Labs Inc | Stock-Other | 3.02% | +4.51% | — | |
| 7 | LYEL | Lyell Immunopharma, Inc. | Stock-Other | 2.74% | +2.71% | — | |
| 8 | ✓ | Turnstone Biologics CORP | Stock-Other | 2.27% | -2.27% | EXIT | |
| 9 | RANI | Rani Therapeutics Holdings-a | Stock-Other | 1.58% | -0.96% | — | |
| 10 | ✓ | Third Harmonic Bio Inc | Stock-Other | 0.79% | -0.79% | EXIT | |
| 11 | LAB | Standard Biotools Inc | Stock-Other | 0.11% | +0.02% | — |
According to official SEC Form 13F filings, Takeda Pharmaceutical Co LTD reported a total U.S. public equity portfolio value of $16.4M across 11 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including HILLEVAX INC, OVID, XILIO THERAPEUTICS INC) accounted for 88.5% of total reported equity market value during Q1 2025.
During Q1 2025, Takeda Pharmaceutical Co LTD's top holdings by market value included HILLEVAX INC (60.2%)、OVID (14.5%)、XILIO THERAPEUTICS INC (6.6%). The largest single position, HILLEVAX INC, represented 60.2% of total portfolio value.
In Q1 2025, Takeda Pharmaceutical Co LTD made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.